Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Go back to Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 2,126,818 | |||||
| Daiichi Sankyo Co Limited Sponsored ADR (AMEX: DSNKY) | Delayed: 18.83 -0.01 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.84 | 52 Week High | $26.24 | |||
| Open | $18.39 | 52 Week Low | $18.86 | |||
| Day High | $18.88 | P/E | N/A | |||
| Day Low | $18.03 | EPS | $0.00 | |||
| Volume | 40,248 | |||||
